...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The breast journal >Utilization of BioZorb implantable device in breast‐conserving surgery
【24h】

Utilization of BioZorb implantable device in breast‐conserving surgery

机译：利用生物扎石可植入装置在哺乳期手术中

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract BioZorb fiducial marker is an implantable device made of six clips to mark the surgical site of tissue removal in three dimensions. The marker facilitates focused radiation therapy, while allowing for tissue ingrowth during the healing process with resorption by the body overtime. Current literature investigating the use of the BioZorb is limited and focused on its value for radiation treatment. Our objective was to investigate the feasibility and surgical complications associated with the BioZorb in breast‐conserving surgery. From April 2015 to June 2018, 89 patients who underwent 91 partial mastectomies with planned adjuvant radiation therapy and placement of the BioZorb. Demographics, type of BioZorb used, complication rate, and postoperative examinations were analyzed. A total of 89 patients who were a median age of 59?years (range 34‐84) underwent 91 operations with BioZorb placement—86.8% underwent a partial mastectomy (n?=?79), and 13.2% underwent a breast wide re‐excision for margins at the time of BioZorb placement (n?=?12). Of the 79 partial mastectomies, 21.5% (n?=?17) were palpable tumors. Location of the tumor and subsequent BioZorb placement was most often in the upper outer quadrant (40.7%), followed by upper inner (27.5%), lower outer (20.9%), and lower inner quadrants (10.9%). 92.3% (n?=?84) had a single BioZorb placed, 5.5% (n?=?5) had two BioZorbs placed in a single lumpectomy cavity, and 2.2% (n?=?2) had two BioZorbs placed in separate lumpectomy cavities of the same breast. Of the 10 different tissue marker sizes used, a 2?×?3?cm BioZorb was most commonly used (37/98, 37.8%), followed by 3?×?4?cm (25/98, 25.5%) and 1?×?3?×?2 (9/98, 9.2%). A total of five patients underwent immediate bilateral breast reduction following placement of the BioZorb. Of the 91 operations, 22 patients had a subsequent reoperation for positive margins after initial placement of the BioZorb, of which 86.4% retained the BioZorb . During these reoperations, only 1 patient had the BioZorb removed due to discomfort (4.5%) and two had it removed due to subsequent mastectomy (9.1%). At a median time of 1.1?years, the BioZorb continued to be palpable on clinical breast examination in 63.6% of patients. The longest time that the BioZorb continued to be palpable was 2.8?years. Additional imaging was ordered because a clinician palpated a mass, unaware it was the BioZorb 8.8% of the time (n?=?8). Thirty‐day complications include 3.3% of patients with an infection requiring antibiotics (n?=?3) and 2.2% with an abscess requiring aspiration and antibiotics without removal of the BioZorb. One patient had migration of the BioZorb from the breast to the axilla which resulted in surgical explant at 9?months post‐op. BioZorb is feasible to use in breast‐conserving surgery with few short‐ and long‐term complications, but will result in a palpable mass that may persist for more than 1?year. Explantation is rare.
机译：摘要Biozorb基准标记是一种由六个夹子制成的可植入装置，用于标记三维组织移除的手术部位。标记有助于聚焦放射疗法，同时允许在愈合过程中的组织成向，并通过身体加班吸收。目前研究使用BioZOBB的文献是有限的，并专注于其对辐射处理的值。我们的目的是探讨与哺乳术手术中生物氮藻相关的可行性和手术并发症。从2015年4月到2018年6月，89名患者接受了91例部分乳化切除术，患有计划的辅助放射治疗和放置生物ZORB。分析了人口统计，使用的生物扎率，并发症率和术后检查。共有89名患者，中位年龄为59岁？年（范围34-84）经历了91个作用，生物扎拼贴-86.8％接受了部分乳房切除术（n？= 79），13.2％接受了乳房宽的乳房生物扎沉积时的边距切除（n？= 12）。在79个部分乳房切除术中，21.5％（N？= 17）是可触及的肿瘤。肿瘤的位置和随后的生物扎夹放置在上外象限（40.7％）中，其次是上内（27.5％），下外（20.9％）和下部内象限（10.9％）。 92.3％（n？=α84）具有单一的生物扎槽，5.5％（n？=Δ5）置于单一的肿瘤切除术腔中的两种生物zorbs，2.2％（n？=Δ2）与分开的两个生物zorbs同一乳房的肿块肿瘤。在使用的10种不同的组织标记尺寸中，最常用的（37/98,37.8％）的2？×3？3？cm Biozorb，其次是3？×4？cm（25/98,25.5％）和1 ？×3？×2（9/98,9.2％）。在放置生物氮藻后，共有五名患者接受了立即双侧乳房减少。在91个操作中，22名患者随后在生物扎率初始放置后重新进食，其中86.4％保留了生物扎率。在这些重新进步期间，只有1例患者由于不适（4.5％），并且由于随后的乳房切除术（9.1％）而被除去两种患者。在1.1的中位数，生物Zorb在63.6％的患者中继续进行临床乳房检查。 Biozorb继续明显的最长时间是2.8？年。订购了额外的成像，因为临床医生触诊了群众，不知道它是生物ZORB 8.8％的时间（n？=？8）。 30天的并发症包括3.3％的患者，感染需要抗生素（n？= 3）和2.2％，脓肿需要吸入和抗生素而不除去生物扎。一名患者迁移了生物血管从乳房迁移到腋下，导致2个月后的手术外科植物。 Biozorb可用于哺乳母乳手术，少量短期和长期并发症，但会导致可触及的肿块，可能持续超过1年以上。渐使是罕见的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号